These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 1948095)
41. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Melo FR; Mourão PA Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401 [TBL] [Abstract][Full Text] [Related]
42. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866 [TBL] [Abstract][Full Text] [Related]
43. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277 [TBL] [Abstract][Full Text] [Related]
44. Thrombin inhibition by antithrombin in the presence of oversulfated dermatan sulfates. Maaroufi RM; Jozefowicz M; Tapon-Bretaudière J; Fischer AM Carbohydr Res; 2006 Apr; 341(5):672-6. PubMed ID: 16442510 [TBL] [Abstract][Full Text] [Related]
45. Selective and dual action orally active inhibitors of thrombin and factor Xa. Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122 [TBL] [Abstract][Full Text] [Related]
46. Disposition of a new heparan sulfate with fibrinolytic activity in the rat. Gervasi GB; Farina C; Bartoli C; Catalani R; Carpita G; Pistelli N Arzneimittelforschung; 1993 Apr; 43(4):445-9. PubMed ID: 8494575 [TBL] [Abstract][Full Text] [Related]
47. Intramuscular dermatan sulfate MF701 in patients with hip fracture: relationship between pharmacokinetics and antithrombotic efficacy. Imbimbo BP; Sié P; Agnelli G; Saivin S; Dupouy D; Damiani M; Houin G; Gianese F Thromb Haemost; 1994 May; 71(5):553-7. PubMed ID: 8091379 [TBL] [Abstract][Full Text] [Related]
48. Preliminary chemical, biochemical, and pharmacological characterization of a low molecular weight dermatan sulphate. Ferrari GP; Marchesini D; Maggi AP Carbohydr Res; 1994 Mar; 255():125-32. PubMed ID: 8181002 [TBL] [Abstract][Full Text] [Related]
49. Direct thrombin inhibitors. Subramaniam B; Park KW Int Anesthesiol Clin; 2005; 43(2):39-53. PubMed ID: 15795561 [No Abstract] [Full Text] [Related]
50. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate. Fabiana Alberto M; Giaquinta Romero D; Lazzari M; Calabrese GC Thromb Res; 2008; 122(1):109-16. PubMed ID: 17936880 [TBL] [Abstract][Full Text] [Related]
51. A survey of the clinical experience with dermatan sulfate. Gianese F; Lucchelli PE Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090 [No Abstract] [Full Text] [Related]
52. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion. Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533 [TBL] [Abstract][Full Text] [Related]
53. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives. Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702 [TBL] [Abstract][Full Text] [Related]